Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic and Pharmacodynamic Evaluation from an Expansion Cohort

The aims of this study were to further define the safety of sorafenib and erlotinib, given at their full approved monotherapy doses, and to correlate pharmacokinetic (PK) and pharmacodynamic (PD) markers with clinical outcome. In addition, a novel PD marker based on the real-time measurement of RAF...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Quintela-Fandino, Miguel, Le Tourneau, Christophe, Duran, Ignacio, Chen, Eric X., Wang, Lisa, Tsao, Ming, Bandarchi-Chamkhaleh, Bizhan, Pham, Nhu-Ann, Do, Trevor, MacLean, Martha, Nayyar, Rakesh, Tusche, Michael W., Metser, Ur, Wright, John J., Mak, Tak W., Siu, Lillian L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2838726/
https://ncbi.nlm.nih.gov/pubmed/20197396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0868
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg